These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30452422)

  • 21. Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial.
    Rodríguez-Cruz M; Cruz-Guzmán ODR; Almeida-Becerril T; Solís-Serna AD; Atilano-Miguel S; Sánchez-González JR; Barbosa-Cortés L; Ruíz-Cruz ED; Huicochea JC; Cárdenas-Conejo A; Escobar-Cedillo RE; Yam-Ontiveros CA; Ricárdez-Marcial EF
    Clin Nutr; 2018 Dec; 37(6 Pt A):1840-1851. PubMed ID: 28987470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy.
    Kumar A; Boriek AM
    FASEB J; 2003 Mar; 17(3):386-96. PubMed ID: 12631578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.
    Acharyya S; Villalta SA; Bakkar N; Bupha-Intr T; Janssen PM; Carathers M; Li ZW; Beg AA; Ghosh S; Sahenk Z; Weinstein M; Gardner KL; Rafael-Fortney JA; Karin M; Tidball JG; Baldwin AS; Guttridge DC
    J Clin Invest; 2007 Apr; 117(4):889-901. PubMed ID: 17380205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy.
    Macaione V; Aguennouz M; Rodolico C; Mazzeo A; Patti A; Cannistraci E; Colantone L; Di Giorgio RM; De Luca G; Vita G
    Acta Neurol Scand; 2007 Feb; 115(2):115-21. PubMed ID: 17212615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity.
    Reay DP; Bastacky SI; Wack KE; Stolz DB; Robbins PD; Clemens PR
    Mol Med; 2015 May; 21(1):442-52. PubMed ID: 26018805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations.
    Bowden SA; Connolly AM; Kinnett K; Zeitler PS
    J Neuromuscul Dis; 2019; 6(1):31-41. PubMed ID: 30614808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
    Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
    Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice.
    Durham WJ; Arbogast S; Gerken E; Li YP; Reid MB
    Muscle Nerve; 2006 Sep; 34(3):298-303. PubMed ID: 16718687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry.
    Cowen L; Mancini M; Martin A; Lucas A; Donovan JM
    BMC Neurol; 2019 May; 19(1):84. PubMed ID: 31046703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
    Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
    Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.
    Connolly AM; Schierbecker J; Renna R; Florence J
    Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
    Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
    Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.